"The Danish pharmaceutical company Novo Nordisk, the maker of GLP-1 for diabetes and obesity, announced it is reducing its workforce globally by 9,000 people by the end of 2026. A company spokesperson declined to provide specific figures for the Boston operations, stating that "this is a global transformation," and Novo Nordisk sites will each be impacted differently. The company has not yet finalized its plans for Boston."
"In a 2024 fact sheet, the company shared that it has 450 employees in Massachusetts, where it has its US Research & Development Hub, with offices in Lexington, Watertown, and Cambridge. In 2023, the company announced it was expanding its research and development presence in the greater Boston area, anticipating that it would add more than 200 jobs. The spokesperson declined to share an updated number of the company's employees in the state but said all "major ongoing projects are expected to continue.""
"According to the announcement, Novo Nordisk expects to reduce around 5,000 of the 78,4000 global positions in Denmark. Novo Nordisk says its rapid growth has added organizational "complexity and costs." To address this, the company plans to shift more investment toward its science, commercial capabilities, and manufacturing expansion. These efforts will focus primarily on growth opportunities in diabetes and obesity, where the company has recently seen a slowdown."
"The aim is to "reach the millions of people who remain untreated," the release said. The company expects the workforce reduction to deliver over $1.25 billion in annualized savings by the end of 2026. "As the global leader in obesity and diabetes, Novo Nordisk delivers life-changing products for patients worldwide," said Mike Doustdar, Novo Nordisk president and CEO, in a statement. "But our markets are evolving, particularly in obesity, a"
Novo Nordisk announced a global workforce reduction of 9,000 positions by the end of 2026, including around 5,000 positions in Denmark. Massachusetts operations include 450 employees across Lexington, Watertown, and Cambridge, and Boston-specific plans remain unfinished. Rapid growth created organizational complexity and costs, prompting a strategic shift of investment toward science, commercial capabilities, and manufacturing expansion. The strategic focus will prioritize growth opportunities in diabetes and obesity after a recent slowdown. The workforce reduction aims to deliver more than $1.25 billion in annualized savings by the end of 2026 while major ongoing projects are expected to continue.
Read at Boston.com
Unable to calculate read time
Collection
[
|
...
]